Quarterly report pursuant to Section 13 or 15(d)

Licensing and Collaborative Agreements (Details Textuals)

v2.4.0.8
Licensing and Collaborative Agreements (Details Textuals) (USD $)
1 Months Ended 3 Months Ended 9 Months Ended 181 Months Ended 12 Months Ended 3 Months Ended 12 Months Ended 24 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended
Feb. 04, 2014
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2013
Dec. 31, 2013
UHN [Member]
Dec. 31, 2012
UHN [Member]
Jun. 30, 2012
US NIH [Member]
Mar. 31, 2010
US NIH [Member]
Mar. 31, 2008
US NIH [Member]
Oct. 31, 2012
Cato [Member]
Dec. 31, 2013
Cato [Member]
Dec. 31, 2012
Cato [Member]
Dec. 31, 2013
Cato [Member]
Dec. 31, 2012
Cato [Member]
Monthly research funding payments               $ 50,000                
Promissory note issuance 390,000           549,500         1,009,000        
Warrant issued with promissory note                       1,009,000        
Research funding payments             309,000                  
Award upon agreed milestones             3,900,000                  
Grant revenue                 187,000 4,600,000 4,200,000          
Research and development expenses   $ 551,300 $ 1,119,600 $ 1,916,100 $ 3,092,200 $ 31,471,800             $ 7,500 $ 124,700 $ 45,000 $ 639,300